Mary L. Schapiro
Known title: DirectorCIK: 0001192486
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
Transaction History
| MS | ▼ Sell | Gift | 2,325 | $0 | 7/28/2026 | View on chart |
| MS | ▼ Sell | Open Market | 1,000 | $212K | 7/28/2026 | View on chart |
| MS | ▲ Buy | Grant | 1,310 | $0 | 6/1/2026 | View on chart |
| MS | ▲ Buy | Grant | 451 | $58K | 6/1/2025 | View on chart |
| MS | ▲ Buy | Grant | 2,155 | $0 | 6/1/2025 | View on chart |
| MS | ▲ Buy | Grant | 379 | $50K | 12/1/2024 | View on chart |
| MS | ▲ Buy | Grant | 2,675 | $0 | 6/1/2024 | View on chart |
| MS | ▲ Buy | Grant | 3,168 | $0 | 6/1/2023 | View on chart |
| MS | ▲ Buy | Grant | 609 | $50K | 6/1/2023 | View on chart |
| MS | ▲ Buy | Grant | 512 | $48K | 12/1/2022 | View on chart |
| MS | ▲ Buy | Grant | 2,945 | $0 | 6/1/2022 | View on chart |
| CVS | ▲ Buy | Grant | 417 | $39K | 11/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Morgan Stanley Q3 earnings met but stock remains under pressure
Morgan Stanley reported strong third-quarter results, yet the stock has not shown a significant reaction. The firm also highlighted stable demand in aerospace and defense and issued a positive signal regarding SpaceX. These developments provide fundamental support, even as the stock trades near its 52-week low and faces technical resistance.
Morgan Stanley Q3 earnings met but stock remains under pressure. Morgan Stanley reported strong third-quarter results, yet the stock has not shown a significant reaction. The firm also highlighted stable demand in aerospace and defense and issued a positive signal regarding SpaceX. These developments provide fundamental support, even as the stock trades near its 52-week low and faces technical resistance.